Rheumatology Advance Access published online on April 17, 2008
Rheumatology, doi:10.1093/rheumatology/ken127
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, UK.
Correspondence to:
K. L. Hyrich, Arthritis Research Campaign Epidemiology Unit, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK. E-mail: kimme.hyrich{at}manchester.ac.uk
 |
Abstract |
|---|
Objectives. Small studies have shown an improvement in disease activity in patients with RA who have switched between anti-TNF therapies for reasons of inefficacy. However, it is not clear whether switching improves longer term outcomes, such as disability. This analysis compares changes in HAQ scores 1 yr following lack of response to a first anti-TNF based on subsequent treatment during that year.
Methods. Analysis was limited to RA patients with inefficacy to a first anti-TNF based on (i) clinician opinion and/or (ii) disease activity score in 28 joints and had an HAQ measured at time of non-response and 12 months later. Patients were classified into three groups based on treatment during the next 12 months: (i) continued anti-TNF despite non-response; (ii) stopped anti-TNF with no further biologics; and (iii) switched to a second anti-TNF. Mean improvement in HAQ was compared among the groups using multivariable linear regression models.
Results. As of July 2006, 868 patients met the inclusion for this analysis. Four hundred and seventy-nine patients stopped anti-TNF of whom 331 switched to a second anti-TNF. Three hundred and eighty-nine continued treatment. Patients who continued and those who switched had improvements in HAQ over the 12 months, unlike patients who discontinued all biologic therapy. The best improvement was seen in those who switched [adjusted mean improvement in HAQ 0.15 (95% CI 0.26, 0.05)].
Conclusion. There is a significant improvement in HAQ in patients who switch to a second anti-TNF, providing an effective next choice of therapy for some patients who fail to respond to their first anti-TNF.
KEY WORDS: Rheumatoid arthritis, Anti-tumour necrosis factor therapy, Disease-modifying anti-rheumatic drugs, Disability, Treatment response, Switching
Submitted 31 December 2007; Accepted 25 February 2008
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Capini, M. Jaturanpinyo, H.-I Chang, S. Mutalik, A. McNally, S. Street, R. Steptoe, B. O'Sullivan, N. Davies, and R. Thomas Antigen-Specific Suppression of Inflammatory Arthritis Using Liposomes J. Immunol., March 15, 2009; 182(6): 3556 - 3565. [Abstract] [Full Text] [PDF]
|
|